Creatine supplements are increasingly used in health and disease. For most people, this will not lead to increases in serum creatinine levels (or declines in estimated GFR). One randomized control trial of patients with diabetes showed no effect on GFR measured using (51)Cr-EDTA clearance, despite higher muscle phosphoryl creatine.A publication referenced below could be read and is referenced below:
Eur J Appl Physiol. 2011 May;111(5):749-56. Epub 2010 Oct 26.
Creatine supplementation may have a therapeutic role in diabetes, but it is uncertain whether this supplement is safe for kidney function. The aim of this study was to investigate the effects of creatine supplementation on kidney function in type 2 diabetic patients. A randomized, double-blind, placebo-controlled trial was performed. The patients were randomly allocated to receive either creatine or placebo for 12 weeks. All the patients underwent exercise training throughout the trial. Subjects were assessed at baseline and after the intervention. Blood samples and 24-h urine samples were obtained for kidney function assessments. Additionally, (51)Cr-EDTA clearance was performed. To ensure the compliance with creatine intake, we also assessed muscle phosphorylcreatine content. The creatine group presented higher muscle phosphorylcreatine content when compared to placebo group.
Creatinine clearance, serum and urinary urea, electrolytes, proteinuria, and albuminuria were unchanged. CR supplementation does not affect kidney function in type 2 diabetic patients, opening a window of opportunities to explore its promising therapeutic role in this population.registration number: NCT00992043.